Gene test 'predicts' lung cancer survival rates

By Admin
New research which has been published in The Lancet medical journal has revealed that a new genetics-based test is able to predict survival rates in lu...

New research which has been published in The Lancet medical journal has revealed that a new genetics-based test is able to predict survival rates in lung cancer patients.

Scientists from the University of California in San Francisco (UCSF) were behind the two international studies and they believe that the molecular gene test is more accurate than current lung cancer diagnostic methods.

It is now hoped the breakthrough will enable doctors to make more informed choices about treatment options.

To read the latest edition of Healthcare Global, click here

There are also aspirations that the gene test could improve the survival chances of thousands of lung cancer patients each year.

The test works by measuring the activity of fourteen genes in cancerous tissue in an attempt to assess how aggressive the tumours will be.

One type of cancer that the gene test works particularly well with is squamous non-small cell lung cancer, often linked to tobacco smoking.

As part of the two independent clinical trials the researchers analysed tissue samples from nearly 1,500 people with early-stage lung cancer in northern California and China.

Both trials revealed that the test could accurately predict whether the odds of death within five years of surgery to remove a lung cancer were low, intermediate, or high.

Commenting on the findings, David Jablons from UCSF, said: “It's quite exciting.

“This has the potential to help hundreds of thousands of people every year survive longer.”

The Healthcare Global magazine is now available on the iPad. Click here to download it.

Share

Featured Articles

McKinsey: Women More Likely to die of Heart Attack Than Men

McKinsey Health Institute's Lucy Pérez says cardiovascular disease top killer of women yet physicians don't know their heart attack symptoms are different

Novo Nordisk Buys $1bn Cardior in CardioVascular Move

As Novo Nordisk expands into heart medicines, we profile the Danish pharma giant who in 1923 was the first to make insulin commercially available

Shoddy Chinese Syringes Sees BD Ramp-up Production

Becton Dickinson – a major supplier of syringes – said it has upped manufacturing in its US facilities after FDA warning on China-made products

AI Tool 'Picks up Early-stage Breast Cancers Doctors Missed'

Technology & AI

AstraZeneca Buys $2bn Fusion in Next-gen Cancer Drugs Move

Medical Devices & Pharma

Eli Lilly and Amazon Pharmacy Partner on Drugs Delivery

Digital Healthcare